复发性胶质瘤再程放疗:结局评估、毒性及预后因素分析——意大利放射肿瘤学协会(AIRO)多中心研究
该多中心研究分析了2002年5月至2017年11月间意大利300例接受再程放疗的复发性胶质瘤患者,中位总生存期为9.7个月,1年和2年总生存率分别为41%和17.7%。低级别胶质瘤组织学、首次放疗间隔>12个月、KPS>70、较年轻年龄、较高总剂量及联合治疗与生存相关。作者认为再程放疗安全可行且毒性有限,联合治疗对特定患者是更好选择。
要点
- 再程放疗的中位间隔时间为16个月,中位生物有效剂量为43 Gy,总剂量范围9 Gy至52.5 Gy。
- 中位总生存期为9.7个月,1年和2年总生存率分别为41%和17.7%。
- 低级别组织学(p≪0.01)、间隔>12个月(p=0.001)、KPS>70(p=0.004)、较年轻(p=0.001)、高总剂量(p=0.04)及联合治疗(p=0.0008)与生存相关。
核心结论
- 作者认为再程放疗是安全可行的治疗,毒性发生率有限,联合治疗对特定患者是更好选择。
- 作者指出识别能获得更大总生存获益的生物有效剂量阈值有助于设计未来前瞻性研究。
研究设计与样本
- 意大利放射肿瘤学协会(AIRO)神经肿瘤研究组开展的多中心研究,收集2002年5月至2017年11月间300例接受再程放疗的复发性胶质瘤患者临床数据。
主要发现
- 再程放疗的中位间隔时间为16个月,再程放疗前手术切除者占19%,同步替莫唑胺(TMZ)者占16.3%,维持化疗者占29%。
- 总剂量范围为9 Gy至52.5 Gy,中位生物有效剂量为43 Gy。
- 中位总生存期为9.7个月,1年和2年总生存率分别为41%和17.7%。
- 低级别胶质瘤组织学(p≪0.01)、间隔>12个月(p=0.001)、KPS>70(p=0.004)、较年轻年龄(p=0.001)、较高总剂量(p=0.04)及联合治疗(p=0.0008)与生存相关。
临床怎么用
- 作者认为再程放疗是安全可行的治疗,毒性发生率有限,联合治疗对特定患者是更好选择。
- 作者指出识别能获得更大总生存获益的生物有效剂量阈值有助于设计未来前瞻性研究。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The prognosis of glioma is dismal, and almost all patients relapsed. At recurrence time, several treatment options are considered, but to date there is no a standard of care. The Neurooncology Study Group of the Italian Association of Radiation Oncology (AIRO) collected clinical data regarding a large series of recurrent glioma patients who underwent re-irradiation (re-RT) in Italy. METHODS: Data regarding 300 recurrent glioma patients treated from May 2002 to November 2017, were analyzed. All patients underwent re-RT. Surgical resection, followed by re-RT with concomitant and adjuvant chemotherapy was performed. Clinical outcome was evaluated by neurological examination and brain MRI performed, 1 month after radiation therapy and then every 3 months. RESULTS: Re-irradiation was performed at a median interval time (IT) of 16 months from the first RT. Surgical resection before re-RT was performed in 19% of patients, concomitant temozolomide (TMZ) in 16.3%, and maintenance chemotherapy in 29%. Total doses ranged from 9 Gy to 52.5 Gy, with a median biological effective dose of 43 Gy. The median, 1, 2 year OS were 9.7 months, 41% and 17.7%. Low grade glioma histology (p ≪ 0.01), IT > 12 months (p = 0.001), KPS > 70 (p = 0.004), younger age (p = 0.001), high total doses delivered (p = 0.04), and combined treatment performed (p = 0.0008) were recorded as conditioning survival. CONCLUSION: our data underline re-RT as a safe and feasible treatment with limited rate of toxicity, and a combined ones as a better option for selected patients. The identification of a BED threshold able to obtain a greater benefit on OS, can help in designing future prospective studies.
引用
- Navarria P, Minniti G, Clerici E, et al. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). J Neurooncol. 2018. PMID: 30515706. doi:10.1007/s11060-018-03059-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。